Tempus AI, Inc. (NASDAQ:TEM) EVP Erik Phelps Sells 5,934 Shares

Tempus AI, Inc. (NASDAQ:TEM) EVP Erik Phelps sold 5,934 shares of the stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $67.57, for a total value of $400,960.38. Following the completion of the sale, the executive vice president now directly owns 214,662 shares of the company’s stock, valued at $14,504,711.34. The trade was a 2.69 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Tempus AI Stock Performance

TEM stock opened at $68.96 on Friday. The stock has a fifty day moving average of $44.36 and a 200-day moving average of $48.84. Tempus AI, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $79.49. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17.

Hedge Funds Weigh In On Tempus AI

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. First Horizon Advisors Inc. bought a new stake in shares of Tempus AI in the third quarter valued at approximately $30,000. Geode Capital Management LLC grew its stake in Tempus AI by 0.4% in the 3rd quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock valued at $7,537,000 after buying an additional 539 shares in the last quarter. FNY Investment Advisers LLC purchased a new position in Tempus AI in the 4th quarter valued at approximately $67,000. IFP Advisors Inc bought a new stake in Tempus AI during the 4th quarter valued at $76,000. Finally, US Bancorp DE purchased a new stake in shares of Tempus AI during the fourth quarter worth $80,000. Institutional investors own 24.22% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on TEM shares. TD Cowen reiterated a “buy” rating and issued a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a report on Wednesday. Piper Sandler reiterated a “neutral” rating and issued a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Needham & Company LLC restated a “buy” rating and issued a $56.00 target price on shares of Tempus AI in a research note on Tuesday, January 14th. Stifel Nicolaus downgraded Tempus AI from a “buy” rating to a “hold” rating and increased their price target for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Finally, Loop Capital cut their price objective on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research report on Tuesday, January 14th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $58.55.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.